Markets & Regulations

(Image: Getty/Evgeny_D)

FDA approves the entrance of two biosimilars

By Ben Hargreaves

US FDA gives approval to Samsung Bioepis’ Humira biosimilar and Pfizer’s Rituxan biosimilar, as the number of such medicines gaining entry onto the US market steadily increases.

(Image: Getty/Rawpixel)

Hired and Retired: A summer of change

By Vassia Barba

As we have entered the summer, companies have taken to refreshing their leadership positions, including at companies such as Gilead, Alnylam, and Maze Therapeutics.

Five biggest CDMO deals of the year

Five deals reshaping the CDMO industry this year

By Ben Hargreaves

The major trend so far in 2019 is the willingness to deploy capital to expand services in the cell and gene therapy sector, and we outline the five most significant deals thus far.

Valneva-GSK sever vaccine alliance

GSK-Valneva end legacy vaccines partnership

By Ben Hargreaves

GSK and Valneva have come to a mutual early termination agreement, as the former looks to ‘allocate capital to fewer, highest priority areas’.

Follow us

Products

View more

Webinars